Halozyme Therapeutics (HALO) Misses Q3 EPS by 3c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $106.49 --0%
EPS Growth %: +23.8%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
PMCB, PLCE, DOMO, More
EPS Growth %: +23.8%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.19), $0.03 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $20.8 million versus the consensus estimate of $24.01 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Medtronic jumps on earnings beat and raised guidance
- Protagonist Therapeutics (PTGX) PT Raised to $170 at H.C. Wainwright
- UBS Downgrades Shanghai Chicmax Cosmetic (2145:HK) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
